Cargando…
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
Luxeptinib (CG-806) simultaneously targets FLT3 and select other kinase pathways operative in myeloid malignancies. We investigated the range of kinases it inhibits, its cytotoxicity landscape ex vivo with acute myeloid leukemia (AML) patient samples, and its efficacy in xenograft models. Luxeptinib...
Autores principales: | Rice, William G., Howell, Stephen B., Zhang, Hongying, Rastgoo, Nasrin, Local, Andrea, Kurtz, Stephen E., Lo, Pierrette, Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256809/ https://www.ncbi.nlm.nih.gov/pubmed/35499387 http://dx.doi.org/10.1158/1535-7163.MCT-21-0832 |
Ejemplares similares
-
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
por: Thieme, Elana, et al.
Publicado: (2022) -
Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021) -
DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models
por: Jiang, Yanyan, et al.
Publicado: (2021) -
Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
por: Piovesan, Dana, et al.
Publicado: (2022) -
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
por: Morris, Joel, et al.
Publicado: (2023)